Madrigal Pharmaceuticals (id:7330 MDGL)
347.45 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/24/2024 3:36:11 AM)
Exchange closed, opens in 1 day 5 hours
7.33 USD (7.33%)
19.22 USD (19.22%)
59.84 USD (59.84%)
48.77 USD (48.77%)
78.63 USD (78.63%)
229.84 USD (229.84%)
213.16 USD (213.16%)
-0.73 USD (-0.73%)
About Madrigal Pharmaceuticals
Market Capitalization 7.39B
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.
| Headquarters (address) |
Four Tower Bridge West Conshohocken 19428 PA United States |
| Phone | 267 824 2827 |
| Website | https://www.madrigalpharma.com |
| Employees | 376 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | MDGL |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 168.25 - 368.29 |
| Market Capitalization | 7.39B |
| P/E trailing | -17.39 |
| P/E forward | -24.29 |
| Price/Sale | 96.27 |
| Price/Book | 9.51 |
| Beta | -0.469 |
| EPS | -25.03 |
| EPS United States (ID:6, base:3402) | 24.22 |